Shares of cruise lines jump after CDC ends Covid-19 program

Shares of cruise lines jump after CDC ends Covid-19 program


NEW YORK, US – JULY 10: An aerial view of the cruise ship “Norwegian Joy” sails up the Hudson River in front of the skyline of Manhattan as the sun sets in New York City, United States on July 10, 2022.

Lokman Vural Elibol | Anadolu Agency | Getty Images

Shares of cruise lines including Carnival, Royal Caribbean and Norwegian rose Tuesday after the U.S. Center for Disease Control ended its Covid-19 program for cruise ships.

The CDC’s program for cruise ships, which became voluntary earlier this year, required all passengers to be tested, encouraged vaccinations for staff and passengers and outlined specific quarantine procedures in the event of an outbreak.

The CDC said it would still provide guidance for cruise ships handling of Covid-19 cases, but that companies can now use their own strategies to mitigate the spread on the virus. That means cruise lines can make their own policies regarding vaccination, testing, and quarantine requirements.

Carnival shares gained about 7% on Tuesday to close at $10.36, while Royal Caribbean shares gained almost 6% to $36.36 and Norwegian shares rose roughly 3.5% to $12.85.

The CDC’s change is expected to give cruise liners more flexibility, which could allow for more travelers on ships and lower costs for the industry.

“While we fully expect the cruise operators to continue to mandate passengers to be vaccinated before sailing,” wrote Steven M. Wieczynski, a Stifel analyst. “We believe today’s news will give the cruise operators more flexibility around the inclusion of younger individuals.”

A Royal Caribbean representative said the company is awaiting further guidance from the CDC before setting its own policies.

The cruise industry has been reeling since the pandemic began, and has more recently been working to recover business back toward pre-2020 levels.



Source

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Health

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]

Read More
FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
Health

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday.  The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]

Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More